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Prevalence and Predictors of Pseudomonas aeruginosa
Among Hospitalized Patients With Diabetic
Foot Infections
Michael P. Veve,1,2, Nicholas J. Mercuro,3 Ryan J. Sangiovanni,4 Maressa Santarossa,5 and Nimish Patel6,

Background. Diabetic foot infections (DFIs) are commonly associated with antibiotic overuse. Empiric DFI treatment often
includes coverage for Pseudomonas aeruginosa (PsA), but the frequency of PsA DFIs is poorly understood. The study objectives
were to quantify the prevalence of and determine predictors for PsA DFIs.
Methods. This multicenter, retrospective cohort included hospitalized patients with DFI from 2013 through 2020 who were age
≥18 years; diabetes mellitus diagnosis; and DFI based on International Classiﬁcation of Diseases, Tenth Revision coding, antibiotic
treatment, and DFI culture with organism growth. Osteomyelitis was excluded. Patient characteristics were described and
compared; the primary outcome was presence of PsA on DFI culture. Predictors of PsA DFI were identiﬁed using multivariable
logistic regression.
Results. Two hundred ninety-two patients were included. The median age was 61 (interquartile range [IQR], 53–69) years; the
majority were men (201 [69%]) and White (163 [56%]). The most commonly isolated organisms were methicillin-susceptible
Staphylococcus aureus (35%) and streptococci (32%); 147 (54%) cultures were polymicrobial. Two hundred ﬁfty-seven (88%)
patients received empiric antibiotics active against PsA, but only 27 (9%) patients had PsA DFI. Immunocompromised status
(adjusted odds ratio [aOR], 4.6 [95% conﬁdence interval {CI}, 1.3–16.7]) and previous outpatient DFI antibiotic treatment
failure (aOR, 4.8 [95% CI, 1.9–11.9]) were associated with PsA DFI.
Conclusions. PsA DFI is uncommon, but most patients receive empiric antipseudomonal antibiotics. Empiric broad-spectrum
antibiotics are warranted given the frequency of mixed infections, but patient-speciﬁc risk factors should be considered before
adding antipseudomonal coverage.
Keywords. diabetic foot infection; Pseudomonas aeruginosa; antimicrobial stewardship.
Diabetic foot infections (DFIs) are an increasingly common
complication from diabetes mellitus that present a signiﬁcant
clinical and economic burden to the healthcare system [1, 2].
Each year, >3 million adults experience a DFI [1], and the corresponding annual cost exceeds $13 billion dollars [2, 3]. DFIs
are estimated to be the most common cause of diabetes-related
hospital admissions, and infection-related readmission rates
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are reported to be as high as 40% [1, 4]. Within current literature, there are several obstacles in determining the appropriate
management and long-term outcomes of patients experiencing
DFIs. These include discrepancies in optimal DFI antibiotic
regimens, treatment durations, intensity of wound care/source
control, and impact of infectious diseases (ID) consultation.
A broad range of pathogens have been implicated in DFIs,
and many infections are polymicrobial [5–7]. This creates a
complexity in selection of appropriate antibiotic therapy decision making, and as a result, several antibiotics are recommended to mitigate DFIs [2, 5, 7]. To further complicate DFI
treatment, multidrug-resistant organisms (MDROs) are of increasing concern in this population [1, 2, 7]. Some of these
MDROs include methicillin-resistant Staphylococcus aureus
(MRSA), vancomycin-resistant Enterococcus species, and
extended-spectrum β-lactamase–producing gram-negative bacilli [2, 7]. The true distribution of these organisms among patients with DFIs is not well characterized and has likely led to
the ubiquitous overprescribing of broad-spectrum antibiotics.
Many clinicians focus on antibiotic coverage targeting
Risk Factors for P aeruginosa DFI • OFID • 1
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METHODS
Study Population

This was a multicenter, retrospective cohort performed at ﬁve
geographically distinct urban acute care centers located
throughout the United States: University of Tennessee
Medical Center (Knoxville, Tennessee), University of
California, San Diego Health (San Diego, California), Loyola
University Medical Center (Chicago, Illinois), Beth Israel
Deaconess Medical Center (Boston, Massachusetts), and Bon
Secours St Francis Hospital (Greenville, South Carolina). This
study received institutional review board approval from all sites
with waiver of consent.
The patient cohort consisted of hospitalized patients with
DFI from January 2013 to December 2020. Patients were included if they (1) were aged ≥18 years; (2) were hospitalized
for ≥24 hours; (3) had DFI as deﬁned by International
Classiﬁcation of Diseases, Ninth and Tenth Revision (ICD-9/
ICD-10) codes for diabetes mellitus and skin and soft tissue infection as described by Fincke et al [8] (ICD-9: 249, 250, 680–
686, 707, 785; ICD-10: E11.621); (4) had documented signs/
symptoms of infection as described in Table 1; (5) had available
DFI cultures with speciated organisms; and (6) received treatment with an antibiotic. Patients with uninfected ulcers or
DFIs with bone involvement were excluded. Individual subjects
2 • OFID • Veve et al

Table 1.

Diabetic Foot Infection Severity Classiﬁcation System

Infection Severity

Criteria

Mild soft tissue infection

Infections limited to skin or superﬁcial
subcutaneous tissues, without local
complication or systemic illness. Additionally,
≥2 manifestations of the following:
• Local swelling or induration
• Erythema (any extending ≤2 cm around the
ulceration)
• Local tenderness or pain
• Local warmth
• Purulent discharge

Moderate/severe soft
tissue infectiona

Either systemically stable or unstable patient with
≥1 of the following:
• Erythema extending >2 cm from the
ulceration, lymphangitis, spread beneath
fascia, deep tissue abscess, or gangrene
• Temperature >38°C (>100.4°F)
• Heart rate >90 beats/min
• Respiratory rate >20 breaths/min or PaCO2
<32 mm Hg
• WBC count >12 000 or <4000 cells/μL or
≥10% immature bands

Source: Modiﬁed Infectious Diseases Society of America and International Working Group
on the Diabetic Foot Infection scoring system [5, 9, 10].
Abbreviations: PaCO2, partial pressure of carbon dioxide; WBC, white blood cell.
a

Can involve muscle, tendon, and joints. Excludes bone involvement.

were included once, and if a subject was eligible over multiple
admissions, the ﬁrst admission meeting either group deﬁnition
was identiﬁed as the index admission or infection.
Data Sources

Data were manually reviewed and extracted from the patients’
electronic medical records. Patient demographics, comorbidities, prior antimicrobial and healthcare exposures, pertinent
laboratory markers (ie, C-reactive protein), healthcare utilization, hospital and intensive care unit admission, severity of illness markers (ie, vasopressor use, Acute Physiology and
Chronic Health Evaluation II [APACHE-II] score), length of
stay, and patient disposition at discharge were collected.
Characteristics of DFI included type (ie, abscess, ulcer), severity, and location. Characteristics associated with diabetes
control were also collected, including glycosylated hemoglobin
A1c (HbA1c) at time of DFI assessment, wound care utilization, and use of and type of outpatient antidiabetic medications. DFI management characteristics collected included
surgical intervention, specialist consultation, antimicrobial
therapy selection, and microbiology data including organism,
culture type, and susceptibilities of isolated organisms per
Clinical and Laboratory Standards Institute breakpoints where
available [11]. Other speciﬁc isolates of interest included gramnegative organisms with laboratory-conﬁrmed extendedspectrum β-lactamase–producing Enterobacterales or that
were carbapenem-resistant. All data were collected with a standardized electronic case report form created through REDCap

Downloaded from https://academic.oup.com/ofid/article/9/7/ofac297/6609549 by Henry Ford Hospital user on 31 August 2022

Pseudomonas aeruginosa (PsA) despite limited evidence to support this practice in the United States [2]. Antibiotics with activity against anaerobes and enteric gram-negative bacilli are
recommended empiric therapies in select moderate to severe
DFIs [5, 6], while the use of antipseudomonal agents is suggested only in patients with general MDRO risk factors [2, 5, 6]. To
prevent the potential overuse of broad-spectrum antibiotics
and antibiotic-related adverse effects, a better understanding
of the pathogen distribution among patients with DFIs is needed. Additionally, there is a need to delineate the clinical and demographic characteristics of the small proportion of DFI
patients actually at risk for PsA compared to those who can
use alternative antibiotics that target the pathogens most likely
encountered in DFIs. This could be advantageous because it
may also expedite transition to oral antibiotics and potentially
facilitate earlier discharge from the hospital.
The purpose of this study was to improve understanding of
the management of patients with DFIs, with a focus on identifying patients who are suitable candidates for targeted empiric
antibiotic therapy. The objectives of this study were to (1) characterize the pathogen distribution observed in patients with
DFIs, (2) identify the clinical/demographic features of patients
most likely to be infected with PsA, and (3) describe empiric
DFI antibiotic therapy treatment practices. The study hypothesis was that PsA DFIs are uncommon, but most patients receive empiric antipseudomonal therapy.

(Research Electronic Data Capture, Vanderbilt University,
Nashville, Tennessee) and hosted on secure internal servers
at each participating site.
Key Deﬁnitions

Statistical Analyses

This study was designed to identify the incidence of and risk
factors for PsA DFI. Assuming a type I error frequency of 5%
and power of 0.8, a minimum of 300 patients were needed to
detect a 15% difference in frequency of outcome between any
2 levels of exposure variables.
In bivariate analyses, categorical variables were compared by
the Pearson χ2 or Fisher exact test; continuous variables were

RESULTS

A total of 292 patients were included in this study: 27 (9%) patients with PsA DFI, and 265 (91%) with non-PsA DFI. Baseline
patient demographics and clinical characteristics of the total
population and between those with and without a PSA DFI
are listed in Table 2. Of those who received outpatient antidiabetic
medications at time of DFI admission, they most commonly included insulin (160 [56%]), metformin (108 [37%]), and sulfonylureas (40 [14%]). Inﬂammatory markers were generally elevated
among the group, as median erythrocyte sedimentation rate and
median C-reactive protein at time of DFI assessment were 67
(interquartile range [IQR], 33–100.5) mm/hour and 11.6 (IQR,
3.4–30.2) mg/L, respectively.
The median age-adjusted Charlson Comorbidity Index was
higher in patients with PsA compared to non-PsA DFI groups
(6 [IQR, 5–8] vs 5 [IQR, 4–7], P = .04). Among the 257 (88%)
patients with HbA1c values, the overall median HbA1C value
prior to hospitalization was 8.3% (IQR, 7.1%–10.0%). HbA1c
was higher in patients with PsA DFI compared to non-PsA
DFI groups (8.5 [IQR, 7.1–10.4] vs 7.3 [IQR, 6.5–8.0],
P = .004). Patients with PsA DFI were also more likely to be
smokers than those without PsA DFI (37% vs 19%, P = .04)
and have an immunocompromised condition (67% vs 30%,
P < .001). Other healthcare exposures, such as prior intravenous or oral antibiotic use within 90 days (56% vs 40%,
P = .11), previous hospitalization within 180 days (41% vs
25%, P = .08), or PsA isolation within the past year from index
DFI admission (4% vs 1%, P = .25), were not different between
PsA and non-PsA DFI groups, respectively. Antipseudomonal agent
use within the past 90 days was also not found to be different between PsA and non-PSA groups (15% vs 13%, P = .77). The median
hospital length of stay was 8 (IQR, 5–13) days and was not different
between PsA and non-PsA DFI groups (9 [IQR, 6–13] vs 8 [IQR,
5–13] days, P = .46).
Patients with PsA DFI more commonly had an “other” DFI
location (37% vs 11%, P < .001) (Table 2), which was primarily
an infection that extended into the ankle (12 [30%]). Patients
with PsA DFI were also more likely to have failed outpatient
Risk Factors for P aeruginosa DFI • OFID • 3
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The primary outcome of interest was the prevalence of PsA isolated from a microbiologic DFI culture. Identiﬁcation of bacterial isolates were determined by conventional methods and
performed by each institution’s local microbiology laboratory
standards of care. Secondary objectives were to describe DFI
antibiotic prescribing patterns and to assess the proportion of
patients who receive empiric anti-PsA therapy, as well as describe antibiotic-related adverse drug events while on therapy.
DFI cultures were categorized into quality and nonquality
types. Quality DFI cultures included deep wound, surgical
wound, abscess drainage, or tissue biopsy; nonquality cultures
included superﬁcial swabs or if the culture location or technique was not described. Patients with positive blood cultures
were considered to be DFI related if they were documented
to be associated with DFI from medical record notes. DFIs
were classiﬁed as mild or moderate/severe severity in accordance to a modiﬁed Infectious Diseases Society of America
and International Working Group on the Diabetic Foot
Infection scoring system (Table 1) [5, 9, 10].
Immunocompromised status was deﬁned as any of the following: history of solid organ transplant, AIDS diagnosis, splenectomy, bone marrow transplant, receipt of chemotherapy or
transplant immunosuppressant in the prior 90 days, receipt of
chronic steroids, or neutropenia at time of care. DFI treatment
was categorized as empiric and deﬁnitive therapy: Empiric antibiotic therapy was deﬁned as antibiotics given prior to organism identiﬁcation from microbiologic cultures, and deﬁnitive
therapy was deﬁned as any antimicrobials given after DFI cultures were ﬁnalized and targeted toward the cultured organism.
Antimicrobial spectrum was categorized to enteric gramnegative coverage, antipseudomonal coverage, anti-MRSA
coverage, or combination therapy including any of the aforementioned groups as determined by 2 infectious diseases pharmacists (M. P. V. and N. P.). Antimicrobial-related adverse
events while on therapy included Clostridioides difﬁcile infection, deﬁned as unexplained and new onset of >3 unformed
stools in past 24 hours or ileus with a positive C difﬁcile stool
sample [12].

compared by the Mann-Whitney U test. Stratiﬁed analyses
were performed to assess the presence/absence of effect modiﬁcation. To determine the patients who have the greatest
likelihood of PsA DFI, variables associated with the outcome
(P < .25) in bivariate analyses were entered into a multivariable
model using a backwards-stepwise approach. Variables
were retained in the model as a potential confounder if
their presence/absence changes the point estimate for antimicrobial therapy by >10%. Model ﬁt was assessed using the
Hosmer-Lemeshow test. All statistical analyses were performed
using SPSS Software for Macintosh version 26.0 (IBM
Corporation, Armonk, New York).

Table 2. Baseline and Infection Characteristics of Patients With Diabetic Foot Infections
Characteristic

Total Population
(N = 292)

PsA DFI
(n = 27)

Non-PsA DFI
(n = 265)

P Valuea

Demographics
Sex, male
Age, y, median (IQR)
Race, White
Active smoker
Active insurance coverage
Home aid/assisted living

201 (69)
61 (53–69)

16 (63)
64 (62–71)

185 (69)
60 (52–68)

.25
.02

163 (56)

9 (33)

154 (58)

59 (20)

10 (37)

49 (19)

.014

272 (93)

25 (93)

247 (93)

29 (10)

4 (15)

25 (10)

.32

282 (97)

25 (93)

257 (97)

.23

91 (32)

11 (41)

80 (30)

.26

242 (83)

21 (78)

221 (84)

.42

.022
1.0

Type 2 DM
Peripheral artery disease
Active outpatient DM medications
Age-adjusted CCI, median (IQR)
Hospitalization, prior 180 d
Prior antibiotic use, 90 d
Nursing home resident

5 (4–7)

6 (5–8)

5 (4–7)

.04

78 (27)

11 (41)

67 (25)

.084

120 (41)

15 (56)

105 (40)

.11

9 (3)

2 (7)

7 (3)

.2

Immunocompromised conditionb

19 (7)

4 (15)

15 (6)

.09

Failed outpatient DFI antibiotics, preceding 90 d

63 (22)

11 (41)

52 (20)

.01

157 (54)

12 (44)

145 (55)

.31
.12

Infection characteristics
Moderate/severe DFI
DFI location
Toe

128 (44)

8 (30)

120 (45)

Lateral/under foot

85 (29)

6 (22)

79 (30)

.41

Heel

48 (16)

5 (19)

43 (16)

.79

Other

40 (14)

10 (37)

30 (11)

.001

Not listed

25 (9)

1 (4)

24 (9)

.49
.16

Type of DFI
Ulcer

203 (70)

22 (82)

181 (68)

Abscess

61 (21)

3 (11)

58 (22)

Ulcer and abscess

28 (10)

2 (7)

26 (10)

0

17 (6)

ICU stay
APACHE II score, median (IQR)

17 (6)
7 (5–12)

8 (5–11.5)

7 (5–12)

.19
1.0
.38
.92

Treatment characteristics
Infectious diseases consultation

124 (43)

15 (56)

109 (41)

.15

Empiric antibiotic therapy, inpatient
Anti-MRSA

280 (96)

26 (96)

254 (96)

1.0

Anti-PsA

257 (89)

24 (89)

233 (89)

1.0

Antianaerobic

224 (77)

23 (85)

201 (76)

Days of total antibiotic therapy, median (IQR)

16 (12–22)

18 (13–29)

16 (12–22)

.27
.51

Data are presented as No. (%) unless otherwise indicated.
Abbreviations: APACHE II, Acute Physiology and Chronic Health Evaluation II; CCI, Charlson Comorbidity Index; DFI, diabetic foot infection; DM, diabetes mellitus; ICU, intensive care unit;
IQR, interquartile range; MRSA, methicillin-resistant Staphylococcus aureus; PsA, Pseudomonas aeruginosa.
a

Comparisons reﬂective of PsA DFI to non-PsA DFI.

b

Immunocompromised conditions include history of solid organ transplant, AIDS diagnosis, splenectomy, bone marrow transplant, receipt of chemotherapy or transplant
immunosuppressant in the prior 90 days, receipt of chronic steroids, or neutropenia at time of care.

antibiotic treatment for a DFI within the prior 90 days (41% vs
22%, P = .011). Of these patients (63 [22%]), the most common
antibiotics included cephalexin (11 [17%]), doxycycline
(11 [17%]), ciproﬂoxacin (10 [16%]), and trimethoprimsulfamethoxazole (8 [13%]); the majority (84%) did not receive
antibiotic therapy with antipseudomonal coverage.
Five hundred sixty-eight organisms were isolated; 147 (54%)
patients had polymicrobial cultures and the median number of
organisms per patient was 2 (IQR, 1–2). The majority (70%) of
patients had at least 1 quality DFI culture, which were most
4 • OFID • Veve et al

commonly surgical drainage (24%), deep wound culture
(17%), abscess drainage (16%), and tissue biopsy (14%).
Eighty-one (28%) patients had at least 1 nonquality DFI culture
obtained (superﬁcial swabs [18%] and unknown culture type
[10%]). Fifty (17%) patients had a bloodstream infection secondary to DFI, and the median duration of bacteremia was 3
(IQR, 2–5) days. All patients cleared blood cultures, except
1 patient never had repeat blood cultures obtained. Of the 27
patients with a PsA DFI, 19 (70%) had a documented quality
culture obtained, and 1 patient had a PsA bloodstream
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Comorbidities

Table 3. Microbiology of 292 Patients With Diabetic Foot Infections

Organisms

Organisms per 292 Patients,
No. (%)

Gram-positive organisms (n = 349)
MSSA

102 (35)

Streptococcus spp

93 (32)

MRSA

58 (20)

Coagulase-negative staphylococci

40 (14)

Enterococcus faecalis

32 (11)

Enterococcus spp, vancomycin
susceptible

5 (2)

Enterococcus spp, vancomycin
resistant

4 (1)

Enterococcus faecium
Other gram-positive organisms

2 (1)

[15%]), and bedside I&D (29 [10%]). The median time to surgical intervention was not different between PsA and non-PsA
DFI groups (4.5 [IQR, 2.3–6.5] vs 3 [IQR, 2–5] days, P = .18).
Sixty-one (34%) patients required an additional surgical procedure while hospitalized, which was not different between PsA
DFI and non-PsA DFI groups (19% vs 36%, P = .18).
Twenty-two (32%) patients underwent a below-the-knee amputation, which was also not different between PsA DFI and
non-PsA DFI groups (14% vs 34%, P = .41).
Regarding antimicrobial therapy, most patients received empiric treatment with an anti-MRSA agent (280 [96%]), an
anti-PsA agent (257 [88%]), and antianaerobic agent (224
[77%]). The proportion of antipseudomonal agents used was
piperacillin-tazobactam (165 [57%]), antipseudomonal ﬂuoroquinolones (42 [14%]), cefepime (39 [13%]), ceftazidime (31
[11%]), meropenem (14 [5%]), aztreonam (13 [5%]), and aminoglycosides (4 [1%]). Twenty-one of 292 (7%) patients received empiric enteric gram-negative therapy only; 14 (5%)
patients did not receive any empiric gram-negative coverage.
The total median duration of therapy was 16 (IQR, 12–22)
days; this did not differ between PsA and non-PsA DFIs (18
[IQR, 13–29] days vs 16 [IQR, 12–22] days, P = .51). The total
median duration of antipseudomonal therapy was 5 (IQR, 3–9)
days. Three (1%) patients developed C difﬁcile–associated diarrhea while on DFI antibiotic therapy; all of these patients had
non-PsA DFIs.
Results of the bivariate analyses and clinical rationale dictated
the variables selected for inclusion into the multivariate regression model: immunosuppressive status and failed outpatient
DFI antibiotics within the prior 90 days (Table 4). Other variables were excluded from the model because of unmet clinical
or statistical criteria, to preserve the n:k ratio or to prevent inclusion of variables that may covary. In the ﬁnal parsimonious
model, both immunosuppressive status and failed outpatient
DFI antibiotics within the prior 90 days were independently associated with an increased odds of PsA DFI.

13 (4)

Gram-negative organisms (n = 186)
Klebsiella spp

30 (10)

Pseudomonas aeruginosa

27 (9)

Proteus spp

27 (9)

Escherichia coli

26 (9)

Enterobacter spp

23 (8)

Morganella spp

13 (4)

Bacteroides spp

9 (3)

Citrobacter spp

8 (3)

Serratia spp

7 (2)

Providencia spp

7 (2)

Other gram-negative organisms

5 (2)

Acinetobacter baumannii

4 (1)

DISCUSSION

Other organisms (n = 33)
Candida spp
Other anaerobes
Abbreviations:
MRSA,
methicillin-resistant
methicillin-susceptible Staphylococcus aureus.

8 (3)
25 (9)
Staphylococcus

aureus;

MSSA,

This study found that the prevalence of PsA from DFI without
bone involvement to be 9%. This is paradoxical to the proportion (88%) of patients receiving empiric antipseudomonal coverage for a median duration of 5 (IQR, 3–9) days. The most
commonly isolated bacteria were gram-positive, and 26% of
the cohort had mixed gram-positive and gram-negative DFIs.
Additionally, there were low proportions of patients infected
with resistant-phenotype gram-negative organisms or anaerobes, although broad-spectrum gram-negative and anaerobic
therapy was used frequently. Immunocompromised patients
and those who recently failed outpatient DFI antibiotic therapy
were populations identiﬁed to be at an increased risk of PsA
DFI. Overall, these ﬁndings are consistent with other literature
Risk Factors for P aeruginosa DFI • OFID • 5
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infection due to a DFI. Of the 586 organisms cultured, grampositives were predominant (61%), followed by gram-negatives
(30%), and anaerobes or fungi (7%) (Table 3); 75 of 292 (26%)
patients had mixed gram-positive and gram-negative DFI.
The most commonly isolated organisms were methicillinsusceptible S aureus (102 [35%]), Streptococcus spp (93
[32%]), MRSA (58 [20%]), coagulase-negative Staphylococcus
spp (40 [14%]), Enterococcus faecalis (32 [11%]), Klebsiella
spp (30 [10%]), and PsA (27 [9%]). Only 11 (4%) patients
were infected with an extended-spectrum β-lactamase–producing or carbapenem-resistant gram-negative organism.
Podiatry was consulted in 104 (36%) patients (30% PsA DFI
vs 36% non-PsA DFI, P = .50); there were also no differences in
the proportion of patients where infectious diseases (56% PsA
DFI vs 41% non-PsA DFI, P = .50) or surgical (70% PsA DFI vs
55 non-PsA DFI, P = .13) consultants were involved in patient
care. A similar proportion of PsA and non-PsA DFI patients
had surgical interventions performed as a part of their treatment (59% vs 62%, P = .77). The most common surgical interventions included wound debridement (69 [24%]), amputation
(55 [19%]), operating room incision & drainage (I&D) (43

Table 4. Variables Associated With Pseudomonas aeruginosa Diabetic Foot Infection

Characteristic
a

Unadjusted OR (95% CI)

P Value

Adjusted OR
(95% CI)

P Value

2.9 (.89–9.5)

.09

4.6 (1.3–16.7)

.019

Failed outpatient DFI antibiotics, prior 90 d

2.8 (1.2–6.4)

.011

4.8 (1.9–11.9)

.001

Recent surgery, 30 d

4.7 (1.8–11.8)

.003

Not tested

Any immunosuppression

Active smoker or history of smoking

2.6 (1.1–6.0)

.022

Not tested

History of MI

2.2 (.6–8.4)

.19

Not tested

Recent hospitalization, 90 d

2.1 (.9–4.8)

.076

Not tested

Congestive heart failure

1.9 (.76–4.8)

.17

Not tested

0.45 (.13–1.5)

.19

Not tested

0.21 (.08–5.3)

<.001

Not tested

Abbreviations: CI, conﬁdence interval; DFI, diabetic foot infection; MI, myocardial infarction; OR, odds ratio.
a
Immunosuppression: history of solid organ transplant, AIDS diagnosis, splenectomy, bone marrow transplant, receipt of chemotherapy or transplant immunosuppressant in the prior 90
days, receipt of chronic steroids, or neutropenia at time of care.

describing DFI microbiology and expand upon limited previous literature identifying patient-speciﬁc factors associated
with PsA DFI. These data also suggest that real-world treatment of DFI is not congruent with guideline-driven recommendations to avoid empiric use of antipseudomonal
agents in most scenarios, and represent an important implementation gap and target for antimicrobial stewardship programs [6, 7, 13].
The incidence of and predictors for PsA in DFI has been
widely debated, but existing evidence remains limited and/or
conﬂicting. Epidemiologically, PsA DFI have been more commonly isolated in locations with warmer or tropical climates;
however, these populations may not be reﬂective of patients
who reside in other locales [5]. The 2012 Infectious Diseases
Society of America guideline for the diagnosis and treatment
of DFIs, among other medical society guideline consensus, recommends against the empiric use of antipseudomonal agents in
DFIs, except for patients with risk factors (strong recommendation, low-quality evidence), but few studies have examined PsA
risk factors among patients with DFI in the context of local
climate [5–7]. A study from the Detroit Medical Center assessed the prevalence of MDROs from DFI, and identiﬁed
broad risk factors for MDRO and DFI pathogens resistant
to guideline-recommended treatments [14]. Staphylococcus
aureus was the commonly isolated (55%), and PsA was isolated
in 131 of 963 (13.6%) organisms, both which reﬂect similar
distribution to the current article. In a stratiﬁed analysis,
the investigators found only that a history of PSA DFI was independently predictive of PSA DFI. Lebowitz and colleagues
found a higher proportion of PsA DFI in subsequent or
recurrent DFI cases, which is similar to the ﬁndings of the
current study in that patients who failed outpatient DFI
treatment had higher odds of PsA DFI compared to those
who did not [15].
There have been several larger studies assessing DFI microbiology without pathogen-directed risk factor analyses.
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Macdonald and colleagues performed a meta-analysis of patients with diabetic foot ulcers that encompassed 112 studies
from several different countries and included >16 000 patients
[16]. Similar to the current study, S aureus was the predominant organism cultured (21%–26%), whereas PsA was isolated
in 10%–11% based on culturing technique (ie, anaerobic or aerobic). These conclusions, although representative of predominantly countries with tropical locale, support against the
routine use of empiric antipseudomonal therapy. Additional
studies have identiﬁed the prevalence of PsA to be within
7.8%–16.4% [14, 15, 17]. Ultimately, limited studies have evaluated empiric antibiotic decision making in regards to spectrum of antibiotic activity for DFI treatment and in
concordance with national guidelines [7, 13, 18–20].
Identiﬁcation and application of patient-speciﬁc risk factors
is a foundational concept for individualized therapies in infectious diseases and antimicrobial stewardship. This study determined that DFI patients, regardless of severity, are frequently
prescribed empiric antipseudomonal therapy even though
this is not a recommended practice for most patients.
Additionally, >40% of patients with DFI had recent antibiotic
exposures. Many of these patients will also likely require antibiotics in the future for retreatment or new infections due to
the pathophysiology of nonhealing wounds and ulcers [5].
Repeated exposures to a given antibiotic class signiﬁcantly increases the risk of subsequent resistance in PsA. This is problematic, as the available agents with activity against PsA are
limited, particularly for oral therapies. In a case-control study,
Gasink et al examined risk of ﬂuoroquinolone resistance in PsA
among 872 isolates; prior ﬂuoroquinolone exposure (adjusted
odds ratio, 3.4 [95% conﬁdence interval, 2.4–5.0]) was the
only risk factor independently associated with resistance [21].
In a multicenter cohort of >7000 patients with sepsis, each
day of anti-PsA β-lactam conferred an additional 4% risk for
development of new resistance to the anti-PsA [22]. While
our objective was not to determine risk associated with
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anti-PsA agents in patients with DFIs. As DFI are often chronic
recurrent infections, patients are at increased risk for
antimicrobial-associated adverse effects. Antimicrobial stewardship programs should prioritize interventions tailored to
improve antimicrobial use in DFIs, with a focus on avoiding
antipseudomonal agent use when not warranted.
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